Nanōmix is the leader in the development of mobile, affordable point-of-care diagnostics. We offer a handheld testing platform and assays that provide rapid, accurate, quantitative information for use in settings where time-to-diagnosis is critical for clinical decision-making and improved patient care.
Our goal is to expand access to quality healthcare by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote, or alternative settings.
We have tests available or under development to aid in the diagnosis of sepsis, acute kidney injury, and SARS-CoV-2. Results are returned in just 10 minutes.
Nanōmix is highlighted among the companies that could help provide the millions of COVID-19 tests that are needed to support safe re-opening.
The Nanōmix S1 Assay detects and quantifies three key markers in blood to aid in the rapid detection of serious infections, including sepsis and bacteremia. The assay received CE Mark in December 2019 and is currently undergoing review by the U.S. FDA. Read more ▶